New drug combo shows promise in shrinking lung tumors before surgery
NCT ID NCT05775796
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tested whether adding the immunotherapy drug serplulimab to standard chemotherapy before and after surgery helps people with stage II-IIIA non-small cell lung cancer. Thirty patients took part. The main goal was to see how many had a major response in their tumor tissue after treatment. The study also looked at safety and how the immune system responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.